Exploring the Potential of Anti-Inflammatory Peptides as Promising Therapeutic Agents for Ulcerative Colitis: A Systematic Review

BACKGROUND AND OBJECTIVESUlcerative colitis (UC) remains an idiopathic disorder; nonetheless, it is likely linked to the disruption of immune responses in the intestinal lining, imbalance in gut microbial composition, and influences from environmental risk elements. Hence, there is a demand for innovative treatment approaches. Our objective is to comprehensively assess the most recent evidence regarding the use of anti-inflammatory peptides (AIPs) as a novel therapeutic strategy for inflammatory bowel disease (IBD), with a specific emphasis on ulcerative colitis.MATERIALS AND METHODSThis systematic study was carried out in February ۲۰۲۳ following PRISMA ۲۰۲۰ guideline. Published studies that investigate the use of anti-inflammatory peptides for UC treatment in were retrieved through searches of the literature in the Medline, Web of Science, and Cochrane databases.RESULTS AND DISCUSSIONFourteen studies satisfied the predesigned criteria and were involved, in which ۱۰ of them used animal models of UC and ۴ were clinical trials in human. Results showed that H-SN۱, a peptide derived from the snake’s venom and glucagon-like peptide-۲ dimer (GLP-۲②), significantly inhibits TNF cytotoxicity. Moreover, oral administration of AVX-۴۷۰ (bovine-derived, anti-TNF antibody) reduced TNF, MPO, and apoptosis levels in enterocytes. Maintaining gut hemostasis and reversing gut dysbiosis could be effective in UC treatment which Ac۲-۲۶ (a peptide that mimics annexin A۱) were helpful in this condition. AMP-۱۸ (gastrokine-۱) and MBCP (peptide derived from buffalo milk) can aid in preserving the intestinal barrier’s integrity by stabilizing tight junctions (TJs). This could potentially prevent IBD from occurring.CONCLUSION Anti-inflammatory peptides (AIPs) play a role in diminishing inflammation, balancing gut microbiota, and enhancing the integrity of the intestinal barrier. Nonetheless, their efficacy may be constrained by vulnerability to protease degradation or potential harm to host cells. Future investigations ought to concentrate on enhancing their pharmacokinetic attributes to maximize their therapeutic efficacy.

کلیدواژه ها:

Anti-inflammatory peptides ، Ulcerative Colitis ، Anti-microbial peptide ، intestinal barrier’s integrity ، gut dysbiosis